The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial
Lühua Wang(Nankai University), André Goy(Hackensack University Medical Center), Peter Martin(NewYork–Presbyterian Hospital), Lauren S. Maeda(Stanford Medicine), Kristie A. Blum(Emory University), Simon Rule(AstraZeneca (United Kingdom)), Ranjana H. Advani(Stanford Medicine), Sara Rodríguez(Navarre Institute of Health Research), Brad S. Kahl(UW Health University Hospital), Ching-Fai Pang(Pharmacyclics (United States)), Michael E. Williams(University of Virginia), Eric Hedrick(Florida Hospital Cancer Institute)
Cited by 41
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k